Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...

Precision BioSciences, Inc.’s DTIL share price has dipped by 9.90%, which has investors questioning if this is right time to ...

Analysts estimate that Precision BioSciences will report an earnings per share (EPS) of $-2.42. Precision BioSciences bulls ...

The latest price target for Precision BioSciences (NASDAQ:DTIL) was reported by HC Wainwright & Co. on March 28, 2025. The analyst firm set a price target for $60.00 expecting DTIL to rise to ...

DURHAM, N.C. (AP) — DURHAM, N.C. (AP) — Precision BioSciences Inc. (DTIL) on Thursday reported a loss of $20.6 million in its first quarter. On a per-share basis, the Durham, North Carolina ...

Chief Executive Officer of Precision BioSciences. “In addition, the Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV, our lead program for chronic Hepatitis B, is progressing as planned.